Key Data Supporting the Use of Rebyota in Patients With Recurrent C Difficile Infections

Key Takeaways

• Rebyota's FDA approval was based on clinical trial data showing significant reduction in CDI recurrence rates compared to placebo.
• The pivotal trial was a randomized, double-blind, placebo-controlled study demonstrating Rebyota's efficacy in recurrent CDI.
• Target patients are adults with recurrent CDI post-antibiotic treatment, especially those with multiple recurrences and high recurrence risk.